Compare CCCC & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | ARL |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.3M | 258.1M |
| IPO Year | 2020 | N/A |
| Metric | CCCC | ARL |
|---|---|---|
| Price | $1.89 | $16.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 1.5K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | $30,108,000.00 | ★ $49,060,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.04 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $9.43 |
| 52 Week High | $4.26 | $17.00 |
| Indicator | CCCC | ARL |
|---|---|---|
| Relative Strength Index (RSI) | 32.78 | 54.65 |
| Support Level | $1.93 | $15.92 |
| Resistance Level | $2.13 | $16.70 |
| Average True Range (ATR) | 0.12 | 0.39 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 0.00 | 72.22 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.